APGE (APGE) - Stock Analysis
Last updated: Jun 22, 2026
Closed
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong clinical catalyst after Phase 2 APEX Part B met all primary and secondary endpoints on 2026-05-27, supported by major funding, AbbVie deal speculation, and about 61% 21-day momentum.
Loading chart data...
Idea window: 6/22/2026 – 6/29/2026Sector:
AI Analyst Overview
Loading AI Analyst data...
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 22 | Jun 29 | APGE | APGE | Strong clinical catalyst after Phase 2 APEX Part B met all primary and secondary endpoints on 2026-05-27, supported by major funding, AbbVie deal speculation, and about 61% 21-day momentum. | Closed | +0.1% |
| Mar 26 | Apr 2 | APGE | APGE | Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea. | Closed | +7.5% |